230609_Benjamin-Kile_Garvan-Institute

Benjamin_Kile_Garvan-Institute.png

Professor Benjamin Kile, internationally recognised blood cell molecular biologist, will lead Garvan as its next Executive Director.

Garvan appoints respected scientist and research leader as new Executive Director

Garvan Institute of Medical Research is pleased to announce the appointment of Professor Benjamin Kile as the Institute’s incoming Executive Director.

Professor Kile succeeds Professor Chris Goodnow, 

“Professor Kile is a respected scientist and research leader with an impressive track record, and we are delighted to welcome him to Garvan. After a competitive international search, Professor Kile was identified as an outstanding candidate. We are confident that he will take Garvan’s already strong position as a globally respected research organisation and elevate the Institute even higher,” he said.

“On behalf of Garvan, I want to extend my deepest appreciation for Professor Chris Goodnow’s passionate and unwavering leadership of the Institute. While we were saddened that he had to make the difficult decision to step down, we are delighted that he will continue his research program here, including working on a universal COVID-19 vaccine.”

Professor Kile will formally commence the Executive Directorship role in the coming months.

“I am humbled and incredibly excited to be given the opportunity to lead an organisation brimming with such talented, creative and passionate people, who are united in their desire to prevent, diagnose, treat and ultimately cure disease. Garvan has a proud history of rigour, excellence and impact. It also has an incredible network of supporters who share the vision and help drive the Institute ever forward. Together with partners St Vincent’s Hospital, Sydney and UNSW, and world-leading capabilities in genomics, Garvan is poised to make a profound impact in cancer, immunology and precision medicine.”

Professor Kile begins at Garvan on 27 April.